Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

Novo Nordisk's top investor moved to take control of the drugmaker's board on Tuesday, vowing a sharper focus on the key U.S.

Novo Nordisk faces a challenge in tapping into the U.S. mass market for weight-loss drugs. With new board leadership, the ...

Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.” ...

COPENHAGEN (Reuters) -Novo Nordisk shares fell as much as 6.4% in early Friday trade after U.S. President Donald Trump ...

The president said the cost of the drug should be much lower for Americans once negotiations with Novo Nordisk had concluded.

Monlunabant shows significant and clinically meaningful weight loss over 16 weeks in patients with obesity and metabolic ...

Barron’s spoke with Dave Moore, executive vice president of U.S. operations, about Wegovy as a pill, rather than an injection.

() -London-based startup SheMed, which offers personalized weight-loss plans using popular medicines Wegovy and Mounjaro, said on Thursday it has raised $50 million in its Series A funding round to ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss ...

Novo Nordisk and Eli Lilly stocks fell after Trump announced Ozempic prices could drop to $150 monthly from $1,000.